Fate Therapeutics Reports Results for Quarter Ended June 30, 2026

What Happened

• On August 13, 2026, Fate Therapeutics, Inc. (FATE) filed a Form 8-K (Item 2.02) to announce its results of operations and financial condition for the quarter ended June 30, 2026. The company issued a press release with the financial results, which is attached to the filing as Exhibit 99.1. The Form 8-K was signed by Bahram Valamehr, President and Chief Executive Officer, dated August 13, 2026.

Key Details

• Filing date: August 13, 2026 (Form 8-K, Item 2.02 and Item 9.01).
• Reporting period: quarter ended June 30, 2026.
• Exhibit: Press release dated August 13, 2026 attached as Exhibit 99.1 (contains the detailed financial results).
• Signature: Bahram Valamehr, Ph.D., MBA — President and CEO.

Why It Matters

• This 8-K signals that Fate has released its quarterly earnings and related financial metrics (earnings, revenue, cash/operating updates) in the attached press release. Investors should read Exhibit 99.1 for the specific figures and any commentary on performance or guidance, since the 8-K itself references the press release rather than embedding the full results. Quarterly earnings releases can affect the stock price and inform decisions about buy/sell, portfolio allocation, and questions for management at upcoming calls or meetings.